drug
CLADRIBINE
Marketedupdated 3mo agoby EMD Serono Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 14 investigational indications.
all catalysts(1)
Trials studying CLADRIBINE
- phase4Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis
- phase3Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- phase2Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
- phase2A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
- phase2Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
- phase2Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
- phase2Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
- phase2BCL2i CLAG-M in R/R Acute Myeloid Leukemia
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 23, 2038
~12.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Sep 10, 2041method-of-use (U-4395)US 12533408
- Sep 10, 2041method-of-use (U-4399)US 12539329
- Nov 23, 2038method-of-use (U-3411)US 10849919
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that